The Food and Drug Administration Oct. 14 approved Inmazeb for treating Zaire ebolavirus infection in adult and pediatric patients. The drug is a mixture of three monoclonal antibodies (atoltivimab, maftivimab and odesivimab-ebgn) that, when combined, target glycoprotein on the Ebola virus’ surface to block its attachment and entry into the human body.

“Today’s approval highlights the importance of international collaboration in the fight against Ebola virus,” said John Farley, M.D., MPH, director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research. “The urgent need for advanced therapies to combat this infectious disease is clear, and today’s action is a significant step forward in that effort.”

Related News Articles

Headline
The Centers for Disease Control and Prevention today joined the global public health community in marking the end of the Ebola outbreak in the Democratic…
Headline
With Ebola outbreaks in the Democratic Republic of the Congo and Guinea, the Centers for Disease Control and Prevention is reminding U.S. health care personnel…
Headline
Health officials in Guinea Sunday declared an Ebola outbreak in the nation’s southeastern N’Zerekore prefecture after confirming three cases in the rural…
Headline
The Centers for Disease Control and Prevention today joined the global public health community in marking the end of the Ebola outbreak in the Democratic…
Headline
The Democratic Republic of the Congo has reported 100 confirmed or probable Ebola cases and 43 deaths in Equateur Province since June 1, the World Health…
Headline
The Centers for Disease Control and Prevention yesterday joined the World Health Organization to declare the end of the Ebola Virus Disease outbreak in the…